Concomitant AF treatment was documented in 76/160 (47.5%) bleeds treated with rFVIIa, in 60/214 (28.0%) treated with PT, and in 36/45 (80.0%) treated with rFVIIa + PT. This evidence concerns the gene F2 and atrial fibrillation.